Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 32.82M 23.21M 20.37M 19.24M 17.53M 2.22B 33.05M 230M 89.17M 1.14B 87.16M 85.27M 3.65B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 32.59M 23.05M 20.23M 19.1M 17.41M 2.21B 32.82M 229M 88.54M 1.13B 86.55M 84.67M 3.63B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 23.21M
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.32%+0.74%+30.69%+48.58% 404.26B
Weighted average by Cap. +0.02%+1.32%+41.54%+67.83%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.3
Net income -1.71M -1.21M -1.06M -1M -912K -116M -1.72M -11.98M -4.64M -59.13M -4.53M -4.44M -190M -3.53M -2.5M -2.19M -2.07M -1.89M -239M -3.56M -24.78M -9.6M -122M -9.38M -9.18M -393M
Net Debt -113K -79.67K -69.91K -66.02K -60.17K -7.64M -113K -790K -306K -3.9M -299K -293K -12.54M -231K -163K -143K -135K -123K -15.63M -232K -1.62M -626K -7.98M -612K -599K -25.66M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise